Achieving pCR after neoadjuvant therapy has been shown to improve patient prognosis, and markers such as Ki67 and breast cancer’s five molecular subtypes have been suggested as predictive for breast cancer patients [9, 10]. Here, MKI67 is linked to breast carcinoma.